RxDoctor Payments Data

Hanish Singh, MD

Pain Medicine · East Lansing, MINPI 1962736785

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.1%. 2025 is the largest year on record at $4,384, 5.2 times the $843 reported in 2019.

$10,542in general payments, 2019–2025

Across 138 payments — averaging $76.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Nevro Corp.$1K
  • Globus Medical$1K
  • Curonix LLC$1K
  • Abbott$1K
  • Medtronic$913
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$4,51343%
  • Food & beverage$6,00757%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,542 in reported general payments places this provider in the 80th percentile of 139 pain medicine providers in Michigan.

See all pain medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$326,954
Medicare patients
393
Services billed
10,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen11$24,738
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen259$3,732
Lidocaine41$3,464
Buprenorphine11$2,693
Pregabalin167$2,555
Gabapentin235$2,478
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen108$2,128
Diclofenac Sodium25$1,706
Morphine Sulfate ErMorphine Sulfate26$638
Tramadol Hcl113$527
Methocarbamol31$448
Celecoxib18$448
Morphine Sulfate18$341
Methylprednisolone56$289
Cyclobenzaprine Hcl35$288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$21$3,03429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 139 pain medicine providers in Michigan.

Other pain medicine in East Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →